Myopathy caused by a combination rosuvastatin and fenofibrate [1]

Journal of Association of Physicians of India

Volumn 55, Issue FEB., 2007, Pages 152-153

  Dedhia, V ^a   Munsi, S C ^a  

^a JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; FENOFIBRATE; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SULFONAMIDE;

AGED; CASE REPORT; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY ATHEROSCLEROSIS; DRUG INTERACTION; HUMAN; LETTER; MALE; MUSCLE DISEASE; RHABDOMYOLYSIS;

AGED; ANTILIPEMIC AGENTS; CORONARY ARTERIOSCLEROSIS; DRUG INTERACTIONS; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MUSCULAR DISEASES; PROCETOFEN; PYRIMIDINES; RHABDOMYOLYSIS; SULFONAMIDES;

EID: 34247541629     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Paul D Thompson, Priscilla Clarkson, Richard H Karas. Statin-associated myopathy. JAMA 2003;289:1681-90.
2. Eriksson M, Angelin B, Sjoberg S. Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of 'evidence-based medicine'. J Intern Med 2005;257:313-4.
3. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90.
4. Fux R, Morike K, Gundel UF, Hartmann R, Gleiter CH. Ezetimibe and statin-associated myopathy. Ann Intern Med 2004;140:671-2.
5. Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003;92:23-9.